Free shipping on all orders over $ 500

BYL-719

Cat. No. M2104

All AbMole products are for research use only, cannot be used for human consumption.

BYL-719 Structure
Synonym:

Alpelisib; BYL719

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 57  USD57 In stock
2mg USD 39  USD39 In stock
5mg USD 50  USD50 In stock
10mg USD 66  USD66 In stock
50mg USD 98  USD98 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Alpelisib (Byl-719) is an effective, selective PI3Kα inhibitor with oral activity. Alpelisib (Byl-719) was targeted to PIK3CA mutated carcinoma. The IC50 of Alpelisib (Byl-719) against P110 α, P110 γ, p110δ and P110 β were 5 nM, 250 nM, 290 nM and 1200 nM, respectively. It has antitumor activity.

Product Citations
Customer Product Validations & Biological Datas
Source Int J Cancer (2015). Figure 1. BYL719
Method Caspase 3/7 activity assay
Cell Lines HOS and MOS-J cells
Concentrations 25 μM
Incubation Time 24 and 48 hr
Results After 72 hr of treatment, BYL719 significantly inhibited the cell growth of all osteosarcoma cell lines tested in a dosedependent manner with an IC50 ranging from 6 to 15 μM and with the IC90 from 24 to 42 μM at 72 hr.
Chemical Information
Molecular Weight 441.47
Formula C19H22F3N5O2S
CAS Number 1217486-61-7
Solubility (25°C) DMSO 72 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Fabrice Andr, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer

[2] Dejan Juric, et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

[3] Ingrid A Mayer, et al. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer

[4] Christine Fritsch, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials

[5] Pascal Furet, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Related PI3K Products
PI3Kγ inhibitor AZ2 

PI3Kγ inhibitor AZ2 is a highly selective PI3Kγ inhibitor (The pIC50 value for PI3Kγ is 9.3).

NIBR-17 

NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth.

RV-1729 

RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ).

Vulolisib 

Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC50 values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively.

Vps34-IN-4 

Vps34-IN-4 is a potent, selective, and orally active inhibitor of VPS34.

  Catalog
Abmole Inhibitor Catalog




Keywords: BYL-719, Alpelisib; BYL719 supplier, PI3K, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.